Abstract
Since prostaglandins are the glamour compounds of the 70's and cancer has been designated as the target for medical research in this decade, their conjunction seemed inevitable. It is surprising, nevertheless, that a meeting should have occurred in the generally neglected field of the hypercalcemia of cancer. Hypercalcemia is a common complication of many neoplasms, some of which show direct bone involvement whereas others do not. In either case, we usually do not know the mechanism of the hypercalcemia. Only a few tumors have been shown to secrete immunoreactive parathyroid hormone. In this issue of the Journal Powell and his . . .